Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation.

Bertrand-Thiébault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, Foernzler D, Visvikis-Siest S.

Ann Hum Genet. 2008 Mar;72(Pt 2):178-83. doi: 10.1111/j.1469-1809.2007.00417.x.

2.

[Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population].

Fu LQ, Huang F, Wu DZ, Guo JH.

Yao Xue Xue Bao. 2004 Mar;39(3):161-3. Chinese.

PMID:
15171646
3.

Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M.

Br J Clin Pharmacol. 2002 Jun;53(6):596-603.

4.

Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.

Shin DJ, Kwon J, Park AR, Bae Y, Shin ES, Park S, Jang Y.

Yonsei Med J. 2012 Nov 1;53(6):1113-9. doi: 10.3349/ymj.2012.53.6.1113.

5.

Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG.

Fundam Clin Pharmacol. 2007 Aug;21(4):419-26.

PMID:
17635181
6.
7.

Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.

Zand N, Tajik N, Moghaddam AS, Milanian I.

Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):102-5. Erratum in: Clin Exp Pharmacol Physiol. 2007 Apr;34(4):385.

PMID:
17201743
8.

Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.

Rasmussen H, Werge T.

Genet Test. 2008 Mar;12(1):57-8. doi: 10.1089/gte.2007.0055. No abstract available.

PMID:
18373404
9.

CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations.

Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Na-Bangchang K, Tawalee A, Krikreangsak N, Cykleng U, Tassaneeyakul W.

Drug Metab Pharmacokinet. 2006 Aug;21(4):286-90.

10.

[Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers].

Ding HW, Dong WZ, Jiang ZG, Ma X.

Yi Chuan. 2004 Mar;26(2):151-4. Chinese.

PMID:
15639978
11.
12.

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA.

Pharmacogenetics. 2002 Dec;12(9):703-11.

PMID:
12464799
13.

CYP2C19 polymorphism affects personality traits of Japanese females.

Ishii G, Suzuki A, Oshino S, Shiraishi H, Otani K.

Neurosci Lett. 2007 Jan 3;411(1):77-80.

PMID:
17052843
14.

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E.

Clin Pharmacol Ther. 2008 Feb;83(2):322-7.

PMID:
17625515
15.

[Effects of ApoE gene polymorphism on anti-inflammatory action of xuezhikang capsule].

Jiang WM, Fang ZY, Zhu CL, Tang SH.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jan;33(1):35-9. Chinese.

PMID:
23596783
16.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
17.

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS.

J Clin Psychopharmacol. 2006 Aug;26(4):367-72. Erratum in: J Clin Psychopharmacol. 2006 Oct;26(5):523. Wing, Yun-Kowk [corrected to Wing, Yun-Kwok].

PMID:
16855453
18.

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.

Brøsen K, de Morais SM, Meyer UA, Goldstein JA.

Pharmacogenetics. 1995 Oct;5(5):312-7.

PMID:
8563772
19.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
20.

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.

Sugimoto K, Uno T, Yamazaki H, Tateishi T.

Br J Clin Pharmacol. 2008 Mar;65(3):437-9. doi: 10.1111/j.1365-2125.2007.03057.x.

Supplemental Content

Support Center